November 04, 2022
Neoadjuvant treatment with cemiplimab led to near or complete disappearance of cutaneous squamous cell carcinoma in almost 64% of patients set to undergo surgery.
April 15, 2021
Single-agent pembrolizumab yielded robust antitumor activity in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma.
